Cboe BZX
20:01:28 10/12/2024 GMT
5-day change
1st Jan Change
253.96 USD
-0.76%
+1.23%
+33.19%
This article is reserved for members
Not a member ?
Free registration
Alnylam Pharmaceuticals, Inc. Presents at Piper Sandler 36th Annual Healthcare Conference, Dec-05-2024 11:00 AM
12-05
TransMedics Names Gerardo Hernandez as CFO; Shares Fall
12-03
MT
TransMedics Names Gerardo Hernandez as CFO; Updates Full Year 2024 Guidance
12-02
MT
Mirae Asset Downgrades Alnylam Pharmaceuticals to Hold, Price Target is $236
12-02
MT
Analyst recommendations: Constellation Energy, Dell, HP, Target, J Sainsbury...
11-28
Alnylam Pharmaceuticals Insider Sold Shares Worth $422,144, According to a Recent SEC Filing
11-27
MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $422,144, According to a Recent SEC Filing
11-27
MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,309,853, According to a Recent SEC Filing
11-27
MT
KalVista Pharmaceuticals, Inc. Appoints Laurence Reid to Board of Directors
11-26
CI
Sector Update: Health Care Stocks Edge Higher Premarket Monday
11-25
MT
Alnylam Says FDA Accepts Supplemental NDA for Vutrisiran to Treat ATTR Amyloidosis With Cardiomyopathy
11-25
MT
Alnylam Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
11-25
CI
Alnylam Pharmaceuticals, Inc. Presents at Jefferies London Healthcare Conference 2024, Nov-20-2024 09:30 AM
11-20
Alnylam Pharmaceuticals Says Nucresiran Performed Well in Phase 1 Transthyretin Amyloidosis Study
11-18
MT
Lexeo Therapeutics, Inc. Appoints Tolga Tanguler to Its Board of Directors
11-13
CI
Alnylam Pharmaceuticals Shares Fall After Wolfe Downgrade
11-12
MT
Alnylam Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference 2024, Nov-12-2024 08:45 AM
11-12
Wolfe Downgrades Alnylam Pharmaceuticals to Underperform From Peer Perform, Price Target at $205
11-12
MT
Analyst recommendations: Airbnb, Estee Lauder, Fortinet, Robinhood, GSK...
11-12
Analyst recommendations: Amazon.com, Mastercard, Bristol-Myers Squibb Company, Uber Technologies, Regeneron Pharmaceuticals...
11-01
Alnylam Pharmaceuticals Swings to Q3 Non-GAAP Net Loss, Revenue Falls
10-31
MT
Alnylam Pharmaceuticals, Inc., Q3 2024 Earnings Call, Oct 31, 2024
10-31
Earnings Flash (ALNY) ALNYLAM PHARMACEUTICALS Reports Q3 Revenue $500.9M
10-31
MT
Earnings Flash (ALNY) ALNYLAM PHARMACEUTICALS Reports Q3 Loss $-0.50 Per Share
10-31
MT
Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024
10-31
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
ALNY: Dynamic Chart
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. In addition, the Company develops Cemdisiran to treat complement-mediated diseases, Belcesiran for the treatment of alpha-1 liver disease, Elebsiran, Zilebesiran, ALN-APP, ALN-HSD, Fitusiran, and others.
More about the company
Last Close Price
255.89 USD
Average target price
298.77 USD
Spread / Average Target
+16.76%
Consensus
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
Buy
